Abstract:OBJECTIVE:To investigate the expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer (NSCLC). METHODS:Tissue and peripheral blood samples were collected from 49 advanced NSCLC patients treated with gemcitabine plus carboplatin. The expressions of RRM1 and ERCC1 mRNA in tumor tissue and peripheral lymphocytes were detected by real-time fluorescent quantitative PCR. The relationship of gene expression with clinical characteristics,chemotherapy response and prognosis was analyzed. RESULTS:The RRM1 expression in tumor tissues was positively correlated with that in peripheral blood lymphocytes,while no significant correlation was observed between ERCC1 expression in tumor tissues and that in peripheral blood (rs=0.332 and 0.258; P=0.020 and 0.073, respectively). The expression of RRM1 and ERCC1 in tumor tissues peripheral lymphocytes was synchronous (rs=0.634 and 0.351; P<0.001 and 0.013, respectively). There was no significant correlation of gene expression with gender, age, smoking status, performance status, clinical stages and histological types of patients (P>0.05). Significant difference was found in response rate to chemotherapy (P<0.05,P<0.01,P<0.05),median survival time (P<0.05,P<0.01,P<0.05) and 1-year survival rate (P<0.01,<0.05,P<0.05) between patients with low RRM1 and ERCC1 expression levels in tumor tissues or low RRM1 expression levels in peripheral blood and those with high RRM1 and ERCC1 expression levels. The patients with low ERCC1 expression levels in tumor tissues gained higher 2-year survival rate (P<0.05). There was no correlation of the expression of ERCC1 in peripheral blood with the response to chemotherapy and prognosis (P>0.05). CONCLUSION:The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced NSCLC treated with gemcitabine plus carboplatin.

Expression of ERCC 1 mRNA in Non-small Cell Lung Cancer Tissues and Survival Analysis of Patients

Expression of ERCC1 in the Patients with Non-Small-cell Lung Cancer

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

[ERCC1 Expression As a Predictor of Survival after Operation in Stage I Non-Small Cell Lung Cancer Patients].

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

High Expression of ERCC1 is a Poor Prognostic Factor in Chinese Patients with Non-Small Cell Lung Cancer Receiving Cisplatin-Based Therapy

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Expression of ERCC1,RRM1 and BRCA1 in Tissues of Advanced Non-Small Cell Lung Cancer

Expression of RRM1 and ERCC1 Genes in Tumor Tissues and Peripheral Blood Lymphocytes of Advanced Non-Small Cell Lung Cancer

Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

ERCC1 mRNA expression in relation to prognostic of colorectal cancer patients received the standard first-line chemotherapy

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.

Positive Expression of ERCC1 Predicts a Poorer Platinum-Based Treatment Outcome in Chinese Patients with Advanced Non-Small-cell Lung Cancer

Association of EGFR mutation with the mRNA expression of ERCC1, RRM1 and TUBB in non-small cell lung cancer tissues

ERCC1 Protein As a Guide for Individualized Therapy of Late-Stage Advanced Non-Small Cell Lung Cancer.

Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.

Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.]